UNC's 2019 ASCO Update on Margetuximab + Chemo vs Trastuzumab vs Chemo in HER2+, Endocrine Therapy w/ or w/o Ribociclib in Metastatic HR+ Breast Cancer, and Atezolizumab + nabPaclitaxel in mTNBC

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

UNC's 2019 ASCO Update on Margetuximab + Chemo vs Trastuzumab vs Chemo in HER2+, Endocrine Therapy w/ or w/o Ribociclib in Metastatic HR+ Breast Cancer, and Atezolizumab + nabPaclitaxel in mTNBC

By UNC Lineberger Comprehensive Cancer Center FEATURING Emily Ray

183 views

November 22, 2019

The UNC Cancer Network (UNCCN) partners with many communities across North Carolina to enhance cancer ...
read more ↘ care, and to provide support and education for all North Carolinians. Services include twenty-four free oncology lectures, delivered online, annually. All lectures include FREE CNE, ASRT, and ACPE credit. Research to Practice lectures also include FREE CME credit. Details may be found at https://www.unccn.org/
UNCCN is a part of the UNC Lineberger Comprehensive Cancer Center. Please contact us at unccn@unc.edu for more information.
↖ read less

0 Comments